<DOC>
	<DOCNO>NCT00960349</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability cediranib combination Cisplatin plus Fluoropyrimidine ( Capecitabine S-1 ) Japanese patient previously untreated locally advanced metastatic unresectable gastric cancer ( GC ) .</brief_summary>
	<brief_title>Study Cediranib Plus Cisplatin Plus Capecitabine/S-1 Japanese Gastric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histological cytological confirmation gastric adenocarcinoma ( include gastric cardia esophagogastric junction ) Having locally advance metastatic gastric cancer must receive prior systemic therapy locally advanced disease . Previous gastrectomy , neoadjuvant adjuvant therapy receive &gt; 6 month ago acceptable Having mild symptom ordinal daily life include walk simple labour work sit position A history poorly control hypertension rest BP &gt; 150/100 mmHg presence absence stable regimen antihypertensive therapy patient require maximal dos calcium channel blocker stabilize BP Significant Haemorrhage ( &gt; 30 ml bleeding/episode previous 3 month ) haemoptysis ( &gt; 5 ml fresh blood previous 4 week ) Arterial thromboembolic event ( include ischemic attack ) previous 12 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Japanese</keyword>
	<keyword>PhI</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Cediranib combination cisplatin plus fluoropyrimidine</keyword>
	<keyword>Cediranib</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>S-1</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Untreated locally advanced metastatic unresectable gastric cancer ( GC )</keyword>
</DOC>